Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy

OncoImmunology

Volumn 4, Issue 1, 2015, Pages 984550-

  Ahmed, Md Selim ^a   Byeon, Se Eun ^a   Jeong, Yideul ^a   Miah, Mohammad Alam ^a   Salahuddin, Md ^a   Lee, Yoon ^a,b   Park, Sung Soo ^c   Bae, Yong Soo ^a,b  

^a Sungkyunkwan University   (South Korea)

^b CreaGene Research Institute   (South Korea)

^c Korea University   (South Korea)

Author keywords

Dab2; dendritic cells; immunogenicity; molecular target

Indexed keywords

ADAPTOR PROTEIN; DISABLED 2 ADAPTOR PROTEIN; GAMMA INTERFERON; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CANCER IMMUNOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; CHEMOLUMINESCENCE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPRECIPITATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; VACCINATION; WESTERN BLOTTING;

EID: 84938718469     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.984550     Document Type: Article

References (51)

1. R.M.Steinman. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:22136168; dx.doi.org/10.1146/annurev-immunol-100311-102839
2. D.Hashimoto, J.Miller, M.Merad. Dendritic cell and macrophage heterogeneity in vivo. Immunity 2011; 35:323-35; PMID:21943488; dx.doi.org/10.1016/j.immuni.2011.09.007
3. M.Merad, P.Sathe, J.Helft, J.Miller, A.Mortha. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604; PMID:23516985; dx.doi.org/10.1146/annurev-immunol-020711-074950
4. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; dx.doi.org/10.1016/j.immuni.2013.07.004
5. C.Prunier, B.A.Hocevar, P.H.Howe. Wnt signaling: physiology and pathology. Growth Factors 2004; 22:141-50; PMID:15518237; dx.doi.org/10.1080/08977190410001720860
6. M.E.Maurer, J.A.Cooper. Endocytosis of megalin by visceral endoderm cells requires the Dab2 adaptor protein. J Cell Sci 2005; 118:5345-55; PMID:16263760; dx.doi.org/10.1242/jcs.02650
7. D.H.Yang, K.Q.Cai, I.H.Roland, E.R.Smith, X.X.Xu. Disabled-2 is an epithelial surface positioning gene. J Biol Chem 2007; 282:13114-22; PMID:17339320; dx.doi.org/10.1074/jbc.M611356200
8. J.A.Kim, S.H.Bae, Y.J.Choi, K.H.Kim, S.S.Park. Feed-back regulation of disabled-2 (Dab2) p96 isoform for GATA-4 during differentiation of F9 cells. Biochem Biophys Res Commun 2012; 421:591-8; PMID:22525672; dx.doi.org/10.1016/j.bbrc.2012.04.051
9. V.Fulop, C.V.Colitti, D.Genest, R.S.Berkowitz, G.K.Yiu, S.W.Ng, J.Szepesi, S.C.Mok. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 1998; 17:419-24; PMID:9696034; dx.doi.org/10.1038/sj.onc.1201955
10. X.X.Xu, T.Yi, B.Tang, J.D.Lambeth. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 1998; 16:1561-9; PMID:9569023; dx.doi.org/10.1038/sj.onc.1201678
11. S.C.Mok, K.K.Wong, R.K.Chan, C.C.Lau, S.W.Tsao, R.C.Knapp, R.S.Berkowitz. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994; 52:247-52; PMID:8314147; dx.doi.org/10.1006/gyno.1994.1040
12. Z.Fazili, W.Sun, S.Mittelstaedt, C.Cohen, X.X.Xu. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999; 18:3104-13; PMID:10340382; dx.doi.org/10.1038/sj.onc.1202649
13. S.Xu, J.Zhu, Z.Wu. Loss of Dab2 expression in breast cancer cells impairs their ability to deplete TGF-beta and induce Tregs development via TGF-beta. PloS One 2014; 9:e91709; PMID:24638085; dx.doi.org/10.1371/journal.pone.0091709
14. N.Jain, H.Nguyen, R.H.Friedline, N.Malhotra, M.Brehm, M.Koyanagi, M.Bix, J.A.Cooper, C.A.Chambers, J.Kang. Cutting edge: Dab2 is a FOXP3 target gene required for regulatory T cell function. J Immunol 2009; 183:4192-6; PMID:19767570; dx.doi.org/10.4049/jimmunol.0902041
15. E.M.Shevach, T.S.Davidson, E.N.Huter, R.A.Dipaolo, J.Andersson. Role of TGF-Beta in the induction of Foxp3 expression and T regulatory cell function. J Clin Immunol 2008; 28:640-6; PMID:18810612; dx.doi.org/10.1007/s10875-008-9240-1
16. S.M.Morris, M.D.Tallquist, C.O.Rock, J.A.Cooper. Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. EMBO J 2002; 21:1555-64; PMID:11927540; dx.doi.org/10.1093/emboj/21.7.1555
17. X.X.Xu, W.Yang, S.Jackowski, C.O.Rock. Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem 1995; 270:14184-91; PMID:7775479; dx.doi.org/10.1074/jbc.270.23.14184
18. V.G.Jokubaitis, M.M.Gresle, D.A.Kemper, W.Doherty, V.M.Perreau, T.L.Cipriani, A.Jonas, G.Shaw, T.Kuhlmann, T.J.Kilpatrick Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis. Acta Neuropathol Commun 2013; 1:32; PMID:24252604; dx.doi.org/10.1186/2051-5960-1-32
19. B.A.Hocevar, A.Smine, X.X.Xu, P.H.Howe. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 2001; 20:2789-801; PMID:11387212; dx.doi.org/10.1093/emboj/20.11.2789
20. C.Prunier, P.H.Howe. Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J Biol Chem 2005; 280:17540-8; PMID:15734730; dx.doi.org/10.1074/jbc.M500974200
21. A.Chaudhury, G.S.Hussey, P.S.Ray, G.Jin, P.L.Fox, P.H.Howe. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol 2010; 12:286-93; PMID:20154680
22. G.S.Hussey, L.A.Link, A.S.Brown, B.V.Howley, A.Chaudhury, P.H.Howe. Establishment of a TGFbeta-induced post-transcriptional EMT gene signature. PloS One 2012; 7:e52624; PMID:23285117; dx.doi.org/10.1371/journal.pone.0052624
23. K.E.Shapira, T.Hirschhorn, L.Barzilay, N.I.Smorodinsky, Y.I.Henis, M.Ehrlich. Dab2 inhibits the cholesterol-dependent activation of JNK by TGF-beta. Mol Biol Cell 2014; 25:1620-8; PMID:24648493; dx.doi.org/10.1091/mbc.E13-09-0537
24. J.Zhou, J.T.Hsieh. The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem 2001; 276:27793-8; PMID:11371563; dx.doi.org/10.1074/jbc.M102803200
25. M.A.Miah, S.E.Byeon, M.S.Ahmed, C.H.Yoon, S.J.Ha, Y.S.Bae. Egr2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity. Eur J Immunol 2013; 43:2484-96; PMID:23716134; dx.doi.org/10.1002/eji.201243046
26. M.A.Miah, C.H.Yoon, J.Kim, J.Jang, Y.R.Seong, Y.S.Bae. CISH is induced during DC development and regulates DC-mediated CTL activation. Eur J Immunol 2012; 42:58-68; PMID:22002016; dx.doi.org/10.1002/eji.201141846
27. L.Passerini, S.E.Allan, M.Battaglia, S.Di Nunzio, A.N.Alstad, M.K.Levings, M.G.Roncarolo, R.Bacchetta. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. Int Immunol 2008; 20:421-31; PMID:18270368; dx.doi.org/10.1093/intimm/dxn002
28. M.A.Burchill, J.Yang, C.Vogtenhuber, B.R.Blazar, M.A.Farrar. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 2007; 178:280-90; PMID:17182565; dx.doi.org/10.4049/jimmunol.178.1.280
29. R.Nyga, C.Pecquet, N.Harir, H.Gu, I.Dhennin-Duthille, A.Regnier, V.Gouilleux-Gruart, K.Lassoued, F.Gouilleux. Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter. Biochem J 2005; 390:359-66; PMID:15833084; dx.doi.org/10.1042/BJ20041523
30. K.Koral, E.Erkan. PKB/Akt partners with Dab2 in albumin endocytosis. Am J Physiol Renal Physiol 2012; 302:F1013-24; PMID:22218591; dx.doi.org/10.1152/ajprenal.00289.2011
31. J.Banchereau, F.Briere, C.Caux, J.Davoust, S.Lebecque, Y.J.Liu, B.Pulendran, K.Palucka. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811; PMID:10837075; dx.doi.org/10.1146/annurev.immunol.18.1.767
32. W.Cao, P.Tan, C.H.Lee, H.Zhang, J.Lu. A transforming growth factor-beta-induced protein stimulates endocytosis and is up-regulated in immature dendritic cells. Blood 2006; 107:2777-85; PMID:16368891; dx.doi.org/10.1182/blood-2005-05-1803
33. F.B.Gertler, R.L.Bennett, M.J.Clark, F.M.Hoffmann. Drosophila abl tyrosine kinase in embryonic CNS axons: a role in axonogenesis is revealed through dosage-sensitive interactions with disabled. Cell 1989; 58:103-13; PMID:2502313; dx.doi.org/10.1016/0092-8674(89)90407-8
34. S.K.Mishra, P.A.Keyel, M.J.Hawryluk, N.R.Agostinelli, S.C.Watkins, L.M.Traub. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J 2002; 21:4915-26; PMID:12234931; dx.doi.org/10.1093/emboj/cdf487
35. C.L.Huang, J.C.Cheng, C.H.Liao, A.Stern, J.T.Hsieh, C.H.Wang, H.L.Hsu, C.P.Tseng. Disabled-2 is a negative regulator of integrin alpha(IIb)beta(3)-mediated fibrinogen adhesion and cell signaling. J Biol Chem 2004; 279:42279-89; PMID:15280374; dx.doi.org/10.1074/jbc.M402540200
36. C.P.Tseng, P.Chang, C.L.Huang, J.C.Cheng, S.S.Chang. Autocrine signaling of platelet-derived growth factor regulates disabled-2 expression during megakaryocytic differentiation of K562 cells. FEBS Lett 2005; 579:4395-401; PMID:16061224; dx.doi.org/10.1016/j.febslet.2005.06.080
37. S.M.Cheong, S.C.Choi, J.K.Han. Xenopus Dab2 is required for embryonic angiogenesis. BMC Dev Biol 2006; 6:63; PMID:17176484; dx.doi.org/10.1186/1471-213X-6-63
38. J.Zhou, J.Scholes, J.T.Hsieh. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem 2003; 278:6936-41; PMID:12473651; dx.doi.org/10.1074/jbc.M210628200
39. J.H.Tong, D.C.Ng, S.L.Chau, K.K.So, P.P.Leung, T.L.Lee, R.W.Lung, M.W.Chan, A.W.Chan, K.W.Lo Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010; 10:253; PMID:20525238; dx.doi.org/10.1186/1471-2407-10-253
40. J.T.O'Malley, S.Sehra, V.T.Thieu, Q.Yu, H.C.Chang, G.L.Stritesky, E.T.Nguyen, A.N.Mathur, D.E.Levy, M.H.Kaplan. Signal transducer and activator of transcription 4 limits the development of adaptive regulatory T cells. Immunology 2009; 127:587-95; PMID:19604309; dx.doi.org/10.1111/j.1365-2567.2008.03037.x
41. M.J.McGeachy, K.S.Bak-Jensen, Y.Chen, C.M.Tato, W.Blumenschein, T.McClanahan, D.J.Cua. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8:1390-7; PMID:17994024; dx.doi.org/10.1038/ni1539
42. F.Rosenbauer, A.Kallies, M.Scheller, K.P.Knobeloch, C.O.Rock, M.Schwieger, C.Stocking, I.Horak. Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J 2002; 21:211-20; PMID:11823414; dx.doi.org/10.1093/emboj/21.3.211
43. D.Chetrit, N.Ziv, M.Ehrlich. Dab2 regulates clathrin assembly and cell spreading. Biochem J 2009; 418:701-15; PMID:19000037; dx.doi.org/10.1042/BJ20081288
44. D.S.Lim, J.H.Kim, D.S.Lee, C.H.Yoon, Y.S.Bae. DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol Immunother 2007; 56:1817-29; PMID:17443323; dx.doi.org/10.1007/s00262-007-0325-0
45. B.Frankenberger, D.J.Schendel. Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol 2012; 91:53-8; PMID:21439674; dx.doi.org/10.1016/j.ejcb.2011.01.012
46. M.Wolfl, P.D.Greenberg. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protocols 2014; 9:950-66; PMID:24675735; dx.doi.org/10.1038/nprot.2014.064
47. C.Zhao, M.W.Wood, E.E.Galyov, U.E.Hopken, M.Lipp, H.C.Bodmer, D.F.Tough, R.W.Carter. Salmonella typhimurium infection triggers dendritic cells and macrophages to adopt distinct migration patterns in vivo. Eur J Immunol 2006; 36:2939-50; PMID:17048271; dx.doi.org/10.1002/eji.200636179
48. C.H.Yoon, E.S.Lee, D.S.Lim, Y.S.Bae. PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc Nat Acad Sci U S A 2009; 106:7852-7; PMID:19416861; dx.doi.org/10.1073/pnas.0812148106
49. C.H.Yoon, M.A.Miah, K.P.Kim, Y.S.Bae. New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers Cdc2 polyubiquitination and G2 arrest under genotoxic stresses. EMBO Rep 2010; 11:393-9; PMID:20395957; dx.doi.org/10.1038/embor.2010.45
50. H.Yokouchi, K.Chamoto, D.Wakita, D.Noguchi, K.Yamazaki, H.Dosaka-Akita, M.Nishimura, H.Ikeda, T.Nishimura. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer. Cancer Sci 2006; 97:148-54; PMID:16441426; dx.doi.org/10.1111/j.1349-7006.2006.00149.x
51. R.Ramakrishnan, D.Assudani, S.Nagaraj, T.Hunter, H.I.Cho, S.Antonia, E.Celis, D.I.Gabrilovich. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120:1111-24; PMID:20234093; dx.doi.org/10.1172/JCI40269